Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial

被引：0
|
作者：
Ergun, Yakup [1 ]
机构：
[1] Antalya City Hosp, Dept Med Oncol, TR-07080 Antalya, Turkiye
来源：
LANCET | 2024年 / 404卷 / 10450期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：337 / 338
页数：2
相关论文
共 50 条
  • [1] TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer
    Rugo, Hope S.
    Bardia, Aditya
    Tolaney, Sara M.
    Arteaga, Carlos
    Cortes, Javier
    Sohn, Joohyuk
    Marme, Frederik
    Hong, Quan
    Delaney, Rosemary J.
    Hafeez, Amir
    Andre, Fabrice
    Schmid, Peter
    [J]. FUTURE ONCOLOGY, 2020, 16 (12) : 705 - 715
  • [2] Health-related quality of life with sacituzumab govitecan in HR+/HER2-metastatic breast cancer in the phase III TROPiCS-02 trial
    Rugo, Hope S.
    Schmid, Peter
    Tolaney, Sara M.
    Dalenc, Florence
    Marme, Frederik
    Shi, Ling
    Verret, Wendy
    Shah, Anuj
    Gharaibeh, Mahdi
    Bardia, Aditya
    Cortes, Javier
    [J]. ONCOLOGIST, 2024, 29 (09): : 768 - 779
  • [3] Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2-metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial
    Marme, Frederik
    Bardia, Aditya
    Rugo, Hope
    Schmid, Peter
    Tolaney, Sara M.
    Oliveira, Mafalda
    Schneeweiss, Andreas
    Shi, Ling
    Verret, Wendy
    Gharaibeh, Mahdi
    Shah, Anju
    Cortes, Javier
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [4] Sacituzumab Govitecan in Metastatic Breast Cancer
    Ganguly, Shuvadeep
    Gogia, Ajay
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03):
  • [5] Sacituzumab-govitecan in metastatic breast cancer
    Lorenz, Judith
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01)
  • [6] Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2-metastatic breast cancer (MBC)
    Rugo, H. S.
    Schmid, P.
    Tolaney, S. M.
    Dalenc, F.
    Marme, F.
    Shi, L.
    Verret, W.
    Gharaibeh, M.
    Bardia, A.
    Cortes, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1258 - S1258
  • [7] Sacituzumab Govitecan in Metastatic Breast Cancer REPLY
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03):
  • [8] Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2-metastatic breast cancer (mBC)
    Heong, V. Y. M.
    Marme, F.
    Rugo, H. S.
    Tolaney, S. M.
    Bardia, A.
    Schmid, P.
    Verret, W.
    Valdez, T.
    Wang, H.
    Cortes, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1486 - S1487
  • [9] Clinical Outcomes by Age Subgroups in the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician's Choice in HR+/ HER2- Metastatic Breast Cancer
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [10] Sacituzumab Govitecan vs Treatment of Physician's Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients With HR+/ HER2- Metastatic Breast Cancer
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 5 - 6
12345